Detalles de la búsqueda
1.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica
; 109(2): 553-566, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646664
2.
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 2021 08 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407608
3.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2417-2426, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196165
4.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528286
5.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol
; 21(7): 978-988, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32511983
6.
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
Br J Haematol
; 204(4): 1178-1192, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38247115
7.
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Lancet Oncol
; 19(10): 1328-1337, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30220622
8.
Perspectives of patients with haematological cancer on how clinicians meet their information needs: "Managing" information versus "giving" it.
Psychooncology
; 27(7): 1719-1726, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29570922
9.
Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.
Blood
; 123(21): 3277-85, 2014 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-24637363
10.
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Haematologica
; 105(12): 2868-2871, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256390
11.
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
Br J Haematol
; 167(3): 346-55, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25040181
12.
Highly Multiplexed and Simultaneous Characterization of Protein and RNA in Single Cells by Flow or Mass Cytometry Platforms Using Proximity Ligation Assay for RNA.
Methods Mol Biol
; 2752: 143-165, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194033
13.
COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis.
EJHaem
; 3(3): 862-872, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35941880
14.
PKCß Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling.
Cancers (Basel)
; 14(23)2022 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497487
15.
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Int J Hematol
; 115(2): 222-232, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34797531
16.
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Clin Lymphoma Myeloma Leuk
; 22(1): 24-33, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34493477
17.
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Cancers (Basel)
; 14(3)2022 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35159058
18.
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Clin Lymphoma Myeloma Leuk
; 22(7): 483-494, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35078739
19.
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Eur J Haematol
; 87(4): 372-5, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21679253
20.
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.
Clin Cancer Res
; 27(20): 5647-5659, 2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380642